Ginkgo Bioworks Holdings, Inc.
DNA
$9.34
-$0.56-5.66%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -33.92% | 33.70% | 15.42% | -90.65% | 74.03% |
| Total Depreciation and Amortization | -98.94% | 2.78% | -1.83% | 304.55% | -77.67% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -21.37% | -24.33% | -24.61% | 39.95% | -69.18% |
| Change in Net Operating Assets | 160.66% | -96.39% | -630.75% | 102.22% | -1,767.36% |
| Cash from Operations | 21.48% | 21.87% | -21.41% | 59.00% | -22.65% |
| Capital Expenditure | 100.00% | 99.50% | 44.41% | 9.14% | 44.18% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -90.36% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -14.04% | 66.58% | -33,737.68% | -86.78% | 2,150.26% |
| Cash from Investing | -13.97% | 67.84% | -1,418.41% | -28.28% | 62.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 75.51% | 52.66% | -1.97% | -1.50% | 0.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 100.00% | -562.50% |
| Cash from Financing | 10,240.82% | 52.66% | -1.97% | 56.34% | -105.75% |
| Foreign Exchange rate Adjustments | -50.00% | 151.35% | 201.37% | -108.57% | -118.75% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 9.29% | 58.43% | -348.67% | 51.14% | -2.45% |